A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
APHINITY
A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
4 other identifiers
interventional
4,804
41 countries
533
Brief Summary
This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 breast-cancer
Started Nov 2011
Longer than P75 for phase_3 breast-cancer
533 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 20, 2011
CompletedFirst Posted
Study publicly available on registry
May 24, 2011
CompletedStudy Start
First participant enrolled
November 8, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 19, 2016
CompletedResults Posted
Study results publicly available
January 5, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
November 28, 2024
CompletedNovember 28, 2025
November 1, 2025
5.1 years
May 20, 2011
December 4, 2017
November 26, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Percentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Percentage of participants with IDFS events (excluding SPNBC) is reported. IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (that is \[i.e.\], an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including ductal carcinoma in situ \[DCIS\] and lobular carcinoma in situ \[LCIS\]) and non-melanoma skin cancer were excluded as an event.
Randomization to the first occurrence of IDFS event (excluding SPNBC) (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Kaplan-Meier estimate of the percentage of participants who were IDFS event-free (excluding SPNBC) at 3 years is reported. IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including DCIS and LCIS) and non-melanoma skin cancer were excluded as an event.
3 years
Secondary Outcomes (38)
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
6, 8, and 10 years
Percentage of Participants With IDFS Event (Including SPNBC), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Randomization to the first occurrence of IDFS event (including SPNBC) (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
3 years
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
6, 8, and 10 years
Percentage of Participants With Disease-Free Survival (DFS) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Randomization to the first occurrence of DFS event (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
- +33 more secondary outcomes
Study Arms (2)
Pertuzumab + Trastuzumab + Chemotherapy
EXPERIMENTALParticipants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\^2 + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).
Placebo + Trastuzumab + Chemotherapy
PLACEBO COMPARATORParticipants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram \[mg/kg\] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m\^2) + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin AUC 6 (up to 900 milligrams \[mg\]).
Interventions
5-Fluorouracil will be administered as per the schedule specified in the respective arm.
Carboplatin will be administered as per the schedule specified in the respective arm.
Cyclophosphamide will be administered as per the schedule specified in the respective arm.
Docetaxel will be administered as per the schedule specified in the respective arm.
Doxorubicin will be administered as per the schedule specified in the respective arm.
Epirubicin will be administered as per the schedule specified in the respective arm.
Paclitaxel will be administered as per the schedule specified in the respective arm.
Pertuzumab will be administered as per the schedule specified in the respective arm.
Placebo will be administered as per the schedule specified in the respective arm.
Trastuzumab will be administered as per the schedule specified in the respective arm.
Eligibility Criteria
You may qualify if:
- Non-metastatic operable primary invasive HER2-positive carcinoma of the breast that is histologically confirmed, and adequately excised
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (\</=) 1
- Known hormone receptor status (estrogen receptor and progesterone receptor)
- The interval between definitive surgery for breast cancer and the first dose of chemotherapy must be no more than 8 weeks (56 days). The first cycle of chemotherapy must be administered within 7 days of randomization or on Day 56, whichever occurs first
- Baseline left ventricular ejection fraction (LVEF) greater than or equal to (\>/=) 55 percent (%) measured by echocardiogram (ECHO) or Multiple-Gated Acquisition (MUGA) Scan
- Confirmed HER2 positive status
- Completion of all necessary baseline laboratory and radiologic investigations prior to randomization
- Women of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception (as defined by the protocol) by the participant and/or partner for the duration of the study treatment and for at least 7 months after the last dose of study drug
You may not qualify if:
- History of any prior (ipsi- and/or contralateral) invasive breast cancer
- History of non-breast malignancies within the 5 years prior to study entry, except for carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinomas of the skin
- Any "clinical" T4 tumor as defined by primary tumor/regional lymph nodes/distant metastasis (TNM), including inflammatory breast cancer
- Any node-negative tumor
- Any previous systemic chemotherapy for cancer or radiotherapy for cancer
- Prior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for cancer
- Concurrent anti-cancer treatment in another investigational trial
- Serious cardiac or cardiovascular disease or condition
- Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness
- Abnormal laboratory tests immediately prior to randomization
- Pregnant or lactating women
- Sensitivity to any of the study medications or any of the ingredients or excipients of these medications
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hoffmann-La Rochelead
- Genentech, Inc.collaborator
- Breast International Groupcollaborator
Study Sites (546)
HonorHealth Research Institute ? Bisgrove
Scottsdale, Arizona, 85258, United States
Providence Regional Medical Center
Everett, California, 98208, United States
Marin Cancer Care Inc
Greenbrae, California, 94904, United States
Kaiser Permanente - Hayward
Hayward, California, 94545, United States
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
Kaiser Permanente - Oakland
Oakland, California, 94611, United States
Kaiser Permanente - Roseville
Roseville, California, 95661, United States
Sutter Cancer Center
Sacramento, California, 95816, United States
Kaiser Permanente Sacramento Medical Center
Sacramento, California, 95825, United States
Southern California Kaiser Permanente
San Diego, California, 92108, United States
K. Permanente - San Fransisco
San Francisco, California, 94115, United States
K. Permanente - San Jose
San Jose, California, 95119, United States
K. Permanente - Santa Clara
Santa Clara, California, 95051, United States
K. Permanente - S. San Fran
South San Francisco, California, 94080, United States
Kaiser Permanente
Vallejo, California, 94589, United States
K. Permanente - Walnut Creek
Walnut Creek, California, 94596, United States
Rocky Mountain Cancer Center - Denver
Denver, Colorado, 80220, United States
Lutheran Hematology &Oncology
Wheat Ridge, Colorado, 80033, United States
Eastern Ct Hema/Onco Assoc
Norwich, Connecticut, 06360, United States
Washington Cancer Institute at MedStar Washington Hospital Center.
Washington D.C., District of Columbia, 20010, United States
Georgetown U
Washington D.C., District of Columbia, 20057, United States
Florida Cancer Specialists
Fort Myers, Florida, 33916, United States
Memorial Cancer Institute
Hollywood, Florida, 33021, United States
Mayo Clinic-Jacksonville
Jacksonville, Florida, 32224, United States
Cancer Specialists
Jacksonville, Florida, 32256, United States
Ocala Oncology Center
Ocala, Florida, 34474, United States
Memorial Breast Cancer Center
Pembroke Pines, Florida, 33028, United States
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, 34952, United States
Florida Cancer Specialists
St. Petersburg, Florida, 33705, United States
Florida Cancer Specialists, Research Department
West Palm Beach, Florida, 33401, United States
Phoebe Putney Memorial Hospital
Albany, Georgia, 31701, United States
Georgia Cancer Specialists
Atlanta, Georgia, 30341, United States
Northwest Georgia Oncology Centers PC - Marietta
Marietta, Georgia, 30060, United States
Kootenai Cancer Center
Post Falls, Idaho, 83854, United States
Rush University Medical Center
Chicago, Illinois, 60612, United States
Uni of Chicago
Chicago, Illinois, 60637, United States
Ingalls Memorial Hospital
Harvey, Illinois, 60426, United States
Loyola University Med Center
Maywood, Illinois, 60153, United States
Edward Cancer Center Naperville
Naperville, Illinois, 60540, United States
Illinois Cancer Care
Peoria, Illinois, 61615-7828, United States
Edward Cancer Center Plainfield
Plainfield, Illinois, 60585, United States
Quincy Medical Group
Quincy, Illinois, 62301, United States
Carle Foundation
Urbana, Illinois, 61801, United States
University of Iowa
Iowa City, Iowa, 52242, United States
Cancer Center of Kansas
Wichita, Kansas, 67214-3728, United States
Cancer Center of Acadiana at Lafayette General
Lafayette, Louisiana, 70503, United States
Cancer Care of Maine
Bangor, Maine, 04401, United States
New England Cancer Specialists
Scarborough, Maine, 04074, United States
Mercy Medical Center
Baltimore, Maryland, 21202, United States
Weinberg CA Inst Franklin Sq
Baltimore, Maryland, 21237, United States
Maryland Oncology & Hematology, PA
Bethesda, Maryland, 20817, United States
Massachusetts General Hospital.
Boston, Massachusetts, 02114, United States
Boston Medical Center
Boston, Massachusetts, 02118, United States
Beth Israel Deac Med Ctr
Boston, Massachusetts, 02215, United States
Dana Farber Can Ins
Boston, Massachusetts, 02215, United States
Berkshire Hematology, Oncology Pc
Pittsfield, Massachusetts, 01201, United States
Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, 49503, United States
West Michigan Cancer Center
Kalamazoo, Michigan, 49007, United States
Southdale Cancer Clinic
Edina, Minnesota, 55414, United States
Coborn Cancer Center
Saint Cloud, Minnesota, 56303, United States
Metro-Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, 55416, United States
Jackson Oncology Associates, PLLC
Jackson, Mississippi, 39202, United States
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Heartland CCOP/Missouri Baptist Medical Center
St Louis, Missouri, 63131, United States
Cancer Alliance of Nebraska
Lincoln, Nebraska, 68510, United States
Cancer Alliance of Nebraska
Omaha, Nebraska, 68106, United States
Dartmouth Hitchcock Med Center
Lebanon, New Hampshire, 03756, United States
Saint Barnabas Medical Center
Livingston, New Jersey, 07039, United States
New York Oncology Hematology, P.C.
Albany, New York, 12206, United States
Roswell Park Cancer Inst.
Buffalo, New York, 14263, United States
Mount Sinai Beth Israel Medical Center
New York, New York, 10003, United States
Mount Sinai Beth Israel Comprehensive Cancer Center
New York, New York, 10011, United States
Mount Sinai West
New York, New York, 10019, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
SUNY Upstate Medical University
Syracuse, New York, 13210, United States
Montefiore Medical Center
The Bronx, New York, 10467, United States
University of North Carolina-Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Carolina Oncology Specialists, PA - Hickory
Hickory, North Carolina, 28602, United States
Oncology Hematology Care Inc
Cincinnati, Ohio, 45242, United States
The Mark H. Zangmeister Ctr
Columbus, Ohio, 43219, United States
Dayton Clinical Oncology Prog
Dayton, Ohio, 45420, United States
Toledo Clinic Cancer Center
Toledo, Ohio, 43623-3536, United States
Northwest Cancer Specialists - Portland (NE Hoyt St)
Portland, Oregon, 97213, United States
Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
Albert Einstein Healthcare Network
Philadelphia, Pennsylvania, 19141, United States
Magee Womens Hospital
Pittsburgh, Pennsylvania, 15213, United States
Charleston Oncology, P .A
Charleston, South Carolina, 29414, United States
Roper Bon Secours St. Francis Cancer Center
Charleston, South Carolina, 29414, United States
South Carolina Oncology Associates - SCRI
Columbia, South Carolina, 29210, United States
University of Missouri-Columbia
Columbia, South Carolina, 65203, United States
Cancer Centers of the Carolina
Greenville, South Carolina, 29615, United States
Sanford USD School of Medicine
Sioux Falls, South Dakota, 57104, United States
Tennessee Oncology , PLLC - Chattanooga
Chattanooga, Tennessee, 37403, United States
Tennessee Oncology - Nashville
Nashville, Tennessee, 37203, United States
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee, 37204, United States
Texas Oncology-Medical City Dallas
Dallas, Texas, 75230, United States
Texas Oncology - DFW at Dallas Presbyterian Hospital
Dallas, Texas, 75231, United States
Texas Oncology - DFW
Dallas, Texas, 75246, United States
Texas Oncology-El Paso Cancer Treatment Center Grandview
El Paso, Texas, 79902, United States
Texas Oncology - DFW Fort Worth
Fort Worth, Texas, 76104, United States
The Center for Cancer and Blood Disorders - Fort Worth
Fort Worth, Texas, 76104, United States
Texas Oncology, P.A. - Garland
Garland, Texas, 77060, United States
Texas Oncology - Houston (Gessner)
Houston, Texas, 77024, United States
Cancer Care Centers of South Texas-HOAST - San Antonio
New Braunfels, Texas, 78130, United States
Texas Oncology - DFW Plano
Plano, Texas, 75075, United States
Texas Oncology-Tyler
Tyler, Texas, 75702, United States
Community Cancer Trials of Utah
Ogden, Utah, 84405, United States
Wellmonth Physician Services
Bristol, Virginia, 24201, United States
Virginia Cancer Institute
Richmond, Virginia, 23230, United States
Providence St. Mary Regional Cancer Center
Walla Walla, Washington, 99362, United States
West Virginia University Hospitals Inc
Morgantown, West Virginia, 26506-9162, United States
Green Bay Oncology/St. Mary?s Hospital
Green Bay, Wisconsin, 54301, United States
Marshfield Clinic
Marshfield, Wisconsin, 54449, United States
Centro Medico San Roque
San Miguel de TucumĂ¡n, T4000IAK, Argentina
Lismore Base Hospital
Lismore, New South Wales, 2480, Australia
Mater Misericordiae Hospital
Sydney, New South Wales, 2060, Australia
Newcastle Mater Misericordiae Hospital
Waratah, New South Wales, 2298, Australia
Westmead Hospital
Westmead, New South Wales, 2145, Australia
Wesley Medical Centre
Auchenflower, Queensland, 4066, Australia
Mater Hospital
Brisbane, Queensland, 4101, Australia
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
Royal Hobart Hospital
Hobart, Tasmania, 7000, Australia
Monash Medical Centre
EAST Bentleigh, Victoria, VIC 3165, Australia
Geelong Hospital
Geelong, Victoria, 3220, Australia
Austin Hospital
Heidelberg, Victoria, 3084, Australia
Peter Maccallum Cancer Institute
Melbourne, Victoria, 3000, Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, 6009, Australia
Lkh-Univ. Klinikum Graz
Graz, 8036, Austria
Tiroler Landeskrankenanstalten Ges.M.B.H.
Innsbruck, 6020, Austria
Ordensklinikum Linz Barmherzige Schwestern
Linz, 4010, Austria
Lhk Feldkirch
Rankweil, 6830, Austria
Lkh Salzburg - Univ. Klinikum Salzburg
Salzburg, 5020, Austria
A. Ă–. Krankenhaus Der Barmherzigen BrĂ¼der
Sankt Veit an der Glan, 9300, Austria
Medizinische Universität Wien; Klinik fĂ¼r Frauenheilkunde
Vienna, 1090, Austria
Medizinische Universität Wien; Klinik fĂ¼r Innere Medizin; Abteilung fĂ¼r Onkologie
Vienna, 1090, Austria
Krankenhaus Der Stadt Wien-Hietzing
Vienna, 1130, Austria
Lkh Vöcklabruck
Vöcklabruck, 4840, Austria
Klinikum Kreuzschwestern Wels
Wels, 4600, Austria
Institut Jules Bordet
Anderlecht, 1070, Belgium
GHdC Site Les Viviers
Charleroi, 6060, Belgium
UZ Antwerpen
Edegem, 2650, Belgium
Jessa Zkh (Campus Virga Jesse)
Hasselt, 3500, Belgium
AZ Groeninge
Kortrijk, 8500, Belgium
UZ Leuven Gasthuisberg
Leuven, 3000, Belgium
CHU de Liège (Sart Tilman)
Liège, 4000, Belgium
Clinique Ste-Elisabeth
Namur, 5000, Belgium
ZAS Sint Augustinus Wilrijk
Wilrijk, 2610, Belgium
UMHAT Tsaritsa Yoanna - ISUL
Sofia, 1527, Bulgaria
SHATO - Sofia
Sofia, 1756, Bulgaria
SHATOD Dr. Marko Antonov Markov-Varna, EOOD
Varna, 9010, Bulgaria
Arthur J.E. Child Comprehensive Cancer Center
Calgary, Alberta, T2N 4N2, Canada
Cross Can Inst
Edmonton, Alberta, T6G 1Z2, Canada
BC Cancer Agency, CSI
Kelowna, British Columbia, V1Y 5L3, Canada
BC Cancer ? Surrey
Surrey, British Columbia, V3V 1Z2, Canada
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
Bcca - Vancouver Island Cancer Centre
Victoria, British Columbia, V8R 6V5, Canada
CancerCare Manitoba
Winnipeg, Manitoba, R2H 2A6, Canada
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, B3H 2Y9, Canada
Northeastern Ontario
Greater Sudbury, Ontario, P3E 5J1, Canada
Hamilton Health Sciences - Juravinski Cancer Centre
Hamilton, Ontario, L8V 5C2, Canada
Cancer Centre of Southeastern Ontario
Kingston, Ontario, K7L 5P9, Canada
London Health Sciences Centre
London, Ontario, N6A 5A5, Canada
Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre
Mississauga, Ontario, L5M 2N1, Canada
Southlake Regional Health Center
Newmarket, Ontario, L3Y 2R2, Canada
Ottawa Regional Cancer Centre
Ottawa, Ontario, K1H 1C4, Canada
Niagara Health Systems - St. Catherines General Site
St. Catharines, Ontario, L2R 7C6, Canada
Sunnybrook Odette Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
Mount Sinai Hospital
Toronto, Ontario, M5G 1Z5, Canada
Princess Margaret Cancer Center
Toronto, Ontario, M5G 1Z5, Canada
Hopital Maisonneuve- Rosemont
Montreal, Quebec, H1T 2M4, Canada
Hopital Sacre-Coeur Research Centre
Montreal, Quebec, H4J 1C5, Canada
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1, Canada
Hopital du Saint Sacrement
Québec, G1J 1Z4, Canada
INTOP
Providencia, 7501089, Chile
Fundacion Arturo Lopez Perez
Santiago, 7500921, Chile
Cancer Hospital Chinese Academy of Medical Sciences.
Beijing, 100021, China
The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)
Beijing, 100071, China
Jilin Cancer Hospital
Changchun, 130012, China
the First Hospital of Jilin University
Changchun, 130021, China
Hu Nan Provincial Cancer Hospital
Changsha, 410006, China
Sichuan Provincial People's Hospital
Chengdu, 610072, China
Fujian Medical University Union Hospital
Fujian, 350001, China
The 900th Hospital of PLA joint service support force
Fuzhou, 110016, China
Sun Yet-sen University Cancer Center
Guangzhou, 510060, China
Guangdong General Hospital
Guangzhou, 510080, China
The First Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, 310003, China
Harbin Medical University Cancer Hospital; Dept. of Breast Surgery
Harbin, 150081, China
Harbin Medical University Cancer Hospital
Harbin, 150081, China
The 1st Affiliated Hospital of Nanchang Unversity
Nanchang, 330006, China
Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)
Shanghai, 200025, China
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
Shanghai First People's Hospital
Shanghai, 200080, China
Changhai Hospital of Shanghai
Shanghai, 200433, China
Hebei Medical University Fourth Hospital
Shijiazhuang, 50011, China
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
Wuhan, 430022, China
Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech
Wuhan, 430030, China
Hubei Cancer Hospital
Wuhan, 430079, China
Fundacion Cardioinfantil
BogotĂ¡, Colombia
Inst. Nacional de Cancerologia
BogotĂ¡, Colombia
Hospital Pablo Tobon Uribe
Medellin-Antioquia, Colombia
Oncomedica S.A.
MonterĂa, Colombia
Uni Hospital Split
Split, 21000, Croatia
General Hospital Varazdin
Varaždin, 42000, Croatia
Clinical Hospital Centre Zagreb
Zagreb, 10000, Croatia
Masarykuv onkologicky ustav
Brno, 656 53, Czechia
Fakultni Nemocnice Hradec Kralove
Hradec KrĂ¡lovĂ©, 500 05, Czechia
Fakultni nemocnice Olomouc
Olomouc, 779 00, Czechia
MULTISCAN, s.r.o., Radiologicke centrum Pardubice
Pardubice, 532 03, Czechia
Aalborg Universitetshospital
Aalborg, 9000, Denmark
Rigshospitalet
Copenhagen, 2100, Denmark
Sydvestjysk Sygehus Esbjerg
Esbjerg, 6700, Denmark
Herlev Hospital
Herlev, 2730, Denmark
Nordsjællands Hospital, Hillerød, Onkologisk Afdeling
Hillerød, 3400, Denmark
Sjællands Universitetshospital, Næstved
Næstved, 4700, Denmark
Odense Universitetshospital, Onkologisk Afdeling R
Odense C, 5000, Denmark
Sygehus Syd Roskilde
Roskilde, 4000, Denmark
Vejle Sygehus
Vejle, 7100, Denmark
Hospital Oncologia
El Salvador, 01101, El Salvador
Clinique De L Europe
Amiens, 80090, France
ICO Paul Papin
Angers, 49000, France
HOP Prive Arras Les Bonnettes
Arras, 62012, France
Institut Sainte Catherine
Avignon, 84000, France
ICONE
Bezannes, 51430, France
Institut Bergonie
Bordeaux, 33076, France
Polyclinique Bordeaux Nord
Bordeaux, 33300, France
Hopital Augustin Morvan
Brest, 29200, France
Centre Francois Baclesse
Caen, 14076, France
Centre Jean Perrin
Clermont-Ferrand, 63011, France
Centre Leonard De Vinci
Dechy, 59187, France
Centre Georges-François Lecler
Dijon, 21034, France
Institut Daniel Hollard
Grenoble, 38000, France
Centre Hospitalier Departemental Les Oudairies
La Roche-sur-Yon, 85925, France
Clinique des Ormeaux
Le Havre, 76600, France
Centre Oscar Lambret
Lille, 59020, France
Hopital Dupuytren
Limoges, 87042, France
Centre Leon Berard
Lyon, 69373, France
Institut Paoli Calmettes
Marseille, 13273, France
Institut régional du Cancer Montpellier
Montpellier, 34298, France
Polyclinique De Gentilly
Nancy, 54100, France
Centre Antoine Lacassagne
Nice, 06189, France
Institut de cancerologie du Gard
Nîmes, 30029, France
Institut Curie
Paris, 75231, France
Ch Pitie Salpetriere
Paris, 75651, France
Polyclinique Francheville
PĂ©rigueux, 24000, France
Clinique Armoricaine Radiologie
Plérin, 22190, France
Chu De Poitiers
Poitiers, 86021, France
Institut Jean Godinot
Reims, 51056, France
Centre Eugene Marquis
Rennes, 35042, France
Centre Henri Becquerel
Rouen, 76038, France
ICL
Saint Prient En Jarez, 42271, France
Centre Rene Huguenin
Saint-Cloud, 92210, France
Ico Rene Gauducheau
Saint-Herblain, 44805, France
Institut d'oncologie de l'Orangerie
Strasbourg, 67010, France
Hopital Hautepierre
Strasbourg, 67098, France
Institut Claudius Regaud
Toulouse, 31052, France
Clinique Pasteur
Toulouse, 31076, France
Centre Alexis Vautrin
VandÅ“uvre-lès-Nancy, 54511, France
Institut Gustave Roussy
Villejuif, 94800, France
Gesundheitszentrum St. Marien GmbH
Amberg, 92224, Germany
Hochwaldkrankenhaus
Bad Nauheim, 61231, Germany
Praxis Dr. Schoenegg
Berlin, 10719, Germany
HELIOS Klinikum Berlin-Buch
Berlin, 13125, Germany
Frauenarzt-Zentrum Zehlendorf an der Teltower Eiche
Berlin, 14169, Germany
Onkologische Schwerpunktpraxis Bielefeld
Bielefeld, 33604, Germany
Universitätsklinikum Bonn
Bonn, 53127, Germany
Klinikum Sindelfingen-Böblingen
Böblingen, 71032, Germany
Praxis Dr. Ralf Lorenz
Braunschweig, 38100, Germany
Hämato-Onkologie im Medicum/Home
Bremen, 28209, Germany
Klinikum Chemnitz gGmbH
Chemnitz, 09116, Germany
Uniklinik Köln, Klinik und Poliklinik und Geburtshilfe
Cologne, 50931, Germany
St. Elisabeth Krankenhaus Köln GmbH
Cologne, 50935, Germany
DONAU ISAR Klinikum Deggendorf
Deggendorf, 94469, Germany
St. Johannes-Hospital
Dortmund, 44137, Germany
Universitätsklinikum "Carl Gustav Carus"
Dresden, 01307, Germany
Universitätsklinikum DĂ¼sseldorf
DĂ¼sseldorf, 40225, Germany
Luisenkrankenhaus GmbH & Co. KG., Brustzentrum
DĂ¼sseldorf, 40235, Germany
Praxis fĂ¼r Hamatologie und Onkologie
Erfurt, 99085, Germany
Universitätsklinikum Erlangen
Erlangen, 91054, Germany
Klinikum Esslingen
Esslingen am Neckar, 73730, Germany
Klinik Johann Wolfgang von Goethe Uni
Frankfurt, 60596, Germany
Städtische Kliniken Frankfurt am Main Höchst
Frankfurt, 65929, Germany
Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus
Frankfurt am Main, 60389, Germany
Praxis fĂ¼r Interdisziplinäre Onkologie und Hämatologie GbR
Freiburg im Breisgau, 79110, Germany
Dres.Jochen Wilke und Harald Wagner
FĂ¼rth, 90766, Germany
Universitätsklinikum Greifswald
Greifswald, 17475, Germany
Universitätsklinikum Halle (Saale)
Halle, 06120, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20246, Germany
SANA Klinikum Hameln-Pyrmont
Hamelin, 31785, Germany
Diakovere Henriettenstift, Frauenklinik
Hanover, 30171, Germany
MVZ Onko Medical GmbH Hannover, Ralf Lohse (GeschäftsfĂ¼hrer)
Hanover, 30177, Germany
Nationales Centrum fĂ¼r Tumorerkrankungen (NCT)
Heidelberg, 69120, Germany
Praxisgemeinschaft
Hildesheim, 31134, Germany
Universitätsklinikum des Saarlandes
Homburg/Saar, 66424, Germany
ViDia Christliche Kliniken Karlsruhe, Vincentius-Diakonissen-Kliniken gAG
Karlsruhe, 76135, Germany
Elisabeth-Krankenhaus Brustzentrum
Kassel, 34117, Germany
Klinikum Kassel GmbH
Kassel, 34125, Germany
UNI-Klinikum Campus Kiel Klinik fĂ¼r Gynäkologie und Geburtshilfe
Kiel, 24105, Germany
Klinikum Landshut Frauenklinik
Landshut, 84034, Germany
Sankt Elisabeth Krankenhaus
Leipzig, 04277, Germany
Praxisklinik Krebsheilkunde fĂ¼r Frauen / Brustzentrum (Dres. Kittel/Klare)
Lichtenberg, 10367, Germany
Evangelisches Krankenhaus
Ludwigsfelde, 14974, Germany
Universitätsklinikum Schleswig-Holstein / Campus LĂ¼beck
LĂ¼beck, 23562, Germany
Universitätsmedizin Mainz
Mainz, 55131, Germany
Brustzentrum Rhein-Ruhr Servicegesellschaft mbH
Mönchengladbach, 41061, Germany
Klinikum der Universität MĂ¼nchen
MĂ¼nchen, 80336, Germany
Rotkreuzklinikum MĂ¼nchen
MĂ¼nchen, 80637, Germany
Klinikum rechts der Isar der TU MĂ¼nchen
MĂ¼nchen, 81675, Germany
Universitätsklinikum MĂ¼nster
MĂ¼nster, 48149, Germany
Sana Klinikum Offenbach GmbH
Offenbach, 63069, Germany
Medizinisches Versorgungszentrum am Klinikum Oldenburg GmbH
Oldenburg, 26133, Germany
Hämatologisch/Onkologische Praxis Prof. Dr. Decker, Studienzentrum
Ravensburg, 88212, Germany
Oncologianova GmbH
Recklinghausen, 45657, Germany
RoMed Klinikum Rosenheim
Rosenheim, 83022, Germany
Universitätsfrauen- und Poliklinik am Klinikum Suedstadt
Rostock, 18059, Germany
MVZ fĂ¼r Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -
Stade, 21680, Germany
Klinikum Mutterhaus der Borromaeerinnen gGmbH
Trier, 54290, Germany
Universitätsklinik TĂ¼bingen
TĂ¼bingen, 72076, Germany
Universitätsklinikum Ulm Am Michelsberg
Ulm, 89075, Germany
Dres. Arnd Nusch Naser Ali-Mohammad Kalhori und Werner Langer
Velbert, 42551, Germany
Schwarzwald-Baar Klinikum Klinik fĂ¼r Frauenheilkunde und Geburtshilfe
Villingen-Schwenningen, 78052, Germany
St. Josefs-Hospital Wiesbaden
Wiesbaden, 65189, Germany
Marien-Hospital Witten
Witten, 58452, Germany
Hämatologisch-Onkologische Schwerpunktpraxis Dres. Schlag & Schöttker
WĂ¼rzburg, 97080, Germany
Grupo Angeles
Guatemala City, 01015, Guatemala
Queen Mary Hospital; Dept. of Clinical Oncology
Hong Kong, Hong Kong
Queen Mary Hospital; Surgery
Hong Kong, Hong Kong
Orszagos Onkologiai Intezet
Budapest, 1122, Hungary
Magyar Honvedseg Egeszsegugyi Kozpont
Budapest, H-1134, Hungary
Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika
Debrecen, 4032, Hungary
Petz Aladar Megyei Oktato Korhaz
Győr, 9024, Hungary
BĂ©kĂ©s Megyei PĂ¡ndy KĂ¡lmĂ¡n KĂ³rhĂ¡z
Gyula, 5700, Hungary
BĂ¡cs-Kiskun VĂ¡rmegyei OktatĂ³kĂ³rhĂ¡z
Kecskemét, 6000, Hungary
Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika
Szeged, 6701, Hungary
Cork Uni Hospital
Cork, Ireland
Mater Misericordiae Uni Hospital
Dublin, 7, Ireland
St. James Hospital
Dublin, 8, Ireland
Beaumont Hospital
Dublin, 9, Ireland
St Vincent'S Uni Hospital
Dublin, Ireland
Galway University Hospital
Galway, Ireland
University Hospital Limerick - Oncology
Limerick, Ireland
Rambam Medical Center
Haifa, 3109601, Israel
Rabin MC
Petah Tikva, 49100, Israel
Chaim Sheba Medical Center
Ramat Gan, 52621, Israel
Kaplan Medical Center
Rehovot, 76100, Israel
Sourasky / Ichilov Hospital
Tel Aviv, 6423906, Israel
Ospedale Antonio Perrino
Brindisi, Apulia, 72100, Italy
Campus Universitario S.Venuta
Catanzaro, Calabria, 88100, Italy
AORN'S.G.Moscati
Avellino, Campania, 83100, Italy
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Napoli, Campania, 80131, Italy
Ist. Uni Federico Ii
Napoli, Campania, 80131, Italy
Azienda Ospedaliero-Universitaria S.Orsola-Malpighi
Bologna, Emilia-Romagna, 40138, Italy
Ospedale Ramazzini
Carpi, Emilia-Romagna, 41012, Italy
Arcispedale Santa Maria Nuova
Reggio Emilia, Emilia-Romagna, 42100, Italy
Irccs Centro Di Riferimento Oncologico (CRO)
Aviano, Friuli Venezia Giulia, 33081, Italy
Divisione Onc Med dell'Azienda
Udine, Friuli Venezia Giulia, 33100, Italy
Ospedale Belcolle Di Viterbo
Viterbo, Lazio, 01100, Italy
Ente Ospedaliero Ospedali Galliera
Genoa, Liguria, 16128, Italy
Az. Osp. Uni Ria San Martino
Genoa, Liguria, 16132, Italy
IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST)
Genoa, Liguria, 16132, Italy
Asst Degli Spedali Civili Di Brescia
Brescia, Lombardy, 25123, Italy
Asst Di Lecco
Lecco, Lombardy, 23900, Italy
Ospedale Mater Salutis
Legnago, Lombardy, 37045, Italy
Irccs Istituto Europeo Di Oncologia (IEO)
Milan, Lombardy, 20141, Italy
Policlinico di Monza
Monza, Lombardy, 20052, Italy
IRCCS Fondazione Maugeri
Pavia, Lombardy, 27100, Italy
IRCCS Istituto Clinico Humanitas
Rozzano, Lombardy, 20089, Italy
Az. Osp. Di Busto P.O. Di Saronno
Saronno, Lombardy, 21047, Italy
Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo
Candiolo, Piedmont, 10060, Italy
Ospedale S. Croce Di Fano
Fano, The Marches, 61032, Italy
Ospedale Di Bolzano
Bolzano, Trentino-Alto Adige, 39100, Italy
Nuovo Ospedale di Prato S. Stefano - Azienda USL Toscana Centro
Prato, Tuscany, 59100, Italy
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
Perugia, Umbria, 06132, Italy
Azienda Ospedaliera S. Maria - Terni
Terni, Umbria, 05100, Italy
Aichi Cancer Center Hospital, Breast Oncology
Aichi, 464-8681, Japan
Chiba Cancer Center
Chiba, 260-8717, Japan
National Cancer Center Hospital East
Chiba, 277-8577, Japan
Natl Hosp Org Shikoku
Ehime, 791-0280, Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, 811-1395, Japan
Gunma University Hospital
Gunma, 371-8511, Japan
Hiroshima City Hiroshima Citizens Hospital
Hiroshima, 730-8518, Japan
Sagara Hospital
Kagoshima, 892-0833, Japan
St. Marianna University School of Medicine Hospital, Breast and Endocrine Surgery
Kanagawa, 216-8511, Japan
Tokai University Hospital, Breast Surgery
Kanagawa, 259-1193, Japan
Kumamoto Shinto General Hospital
Kumamoto, 862-8655, Japan
Kyoto University Hospital
Kyoto, 606-8507, Japan
Niigata Cancer Ctr Hospital
Niigata, 951-8566, Japan
Iwate Med Univ School of Med
Numakunai, 028-3695, Japan
National Hospital Organization Osaka National Hospital
Osaka, 540-0006, Japan
Osaka International Cancer Institute
Osaka, 541-8567, Japan
Saitama Medical University International Medical Center
Saitama, 350-1298, Japan
Saitama Cancer Center, Breast Oncology
Saitama, 362-0806, Japan
Shizuoka Cancer Center
Shizuoka, 411-8777, Japan
Shizuoka General Hospital
Shizuoka, 420-8527, Japan
Jichi Medical School
Tochigi, 329-0498, Japan
National Cancer Center Hospital
Tokyo, 104-0045, Japan
Tokyo Metropolitan
Tokyo, 113-8677, Japan
The Cancer Inst. Hosp. of JFCR
Tokyo, 135-8550, Japan
Tokyo Medical Uni. Hospital
Tokyo, 160-0023, Japan
Centro Estatal de OncologĂa de Campeche
Campehe, Campeche, 24096, Mexico
Fundacion Rodolfo Padilla Padilla A.C.
LeĂ³n, Guanajuato, 37000, Mexico
NĂºcleo de Especialidades OncolĂ³gicas
Guadalajara, Jalisco, 44670, Mexico
Hospital General de MĂ©xico
Mexico City, Mexico CITY (federal District), 06726, Mexico
Hospital Angeles Metropolitano
Mexico City, Mexico CITY (federal District), 06760, Mexico
Centro Universitario Contra El Cancer
Monterrey, Nuevo LeĂ³n, 64020, Mexico
Centro de DiagnĂ³stico y Tratamiento Integral de Mama, Hospital San JosĂ© Tec de Monterrey
Montrrey, Nuevo LeĂ³n, 64710, Mexico
Oaxaca Site Management Organization
Oaxaca City, Oaxaca, 68000, Mexico
MĂ©dicos Especialistas en CĂ¡ncer SC
Aguascalientes, 20230, Mexico
Centro Estatal De Cancerologia De Durango
Durango, 34000, Mexico
Cancerologia de Queretaro
Querétaro, 76178, Mexico
Medisch Centrum Alkmaar
Alkmaar, 1815 JD, Netherlands
Amphia ziekenhuis, locatie langendijk
Breda, 4819 EV, Netherlands
Reinier de Graaf Gasthuis
Delft, 2625 AD, Netherlands
Academish Ziekenhuis Maastricht (Azm)
Maastricht, 6229 HX, Netherlands
Isala Klinieken
Zwolle, 8011 JW, Netherlands
Waikato Hospital
Hamilton, 3240, New Zealand
Palmerston North Hospital
Palmerston North, 4442, New Zealand
Centro Oncologico America
Panama City, 0834-02723, Panama
The Panama Clinic
Panama City, 32400, Panama
Instituto Nacional de Enfermedades Neoplasicas
Lima, 34, Peru
Clinica Anglo Americana - Centro de Investigacion Oncologia CAA
Lima, L27, Peru
Clinica El Golf
San Isidro, L27 Lima, Peru
Clinica Peruana Americana
Trujillo, 13011, Peru
University Of Santo Tomas
Manila, 1008, Philippines
Rizal Medical Center
Pasig, 1605, Philippines
Veterans Memorial Medical Ctr
Quezon City, Luzon, 1101, Philippines
Bialostockie Ctr Onkologii
Bialystok, 15-027, Poland
Centrum Onkologii
Bydgoszcz, 85-796, Poland
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
Gda?sk, 80-214, Poland
Opolskie Centrum Onkologii
Opole, 45-060, Poland
Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad
Warsaw, 02-781, Poland
NZOZ Mazowiecki Szpital Onkologiczny Uczelni Warszawskiej im. M. Sk?odowskiej-Curie
Wieliszew, 05-135, Poland
Emergency University Bucharest Hospital
Bucharest, 050098, Romania
Oncology Inst. Cluj-Napoca
Cluj-Napoca, 400015, Romania
Prof. Dr. I. Chiricuta Institute of Oncology
Cluj-Napoca, 400015, Romania
Euroclinic Center of Oncology SRL
Iași, 700106, Romania
S.I. Russian Oncological Research Center n.a. N.N. Blokhin
Moscow, Moscow Oblast, 115478, Russia
State Budget Institution of Healthcare of Stavropol region Pyatigorsk Oncology Dispensary
Pyatigorsk, Stavropol Kray, 357502, Russia
Clinical Oncology Dispensary of Ministry of Health of Tatarstan
Kazan', Tatarstan Republic, 420029, Russia
SBI of Healthcare Samara Regional Clinical Oncology Dispensary
Samara, 443031, Russia
SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary
Stavropol, 355045, Russia
Tula Regional Oncology Dispensary
Tula, 300053, Russia
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
National Hospital
Bloemfontein, 9301, South Africa
Wits Donald Gordon Clinical Trial Centre
Johannesburg, 2193, South Africa
Steve Biko Academic Hospital
Pretoria, 0002, South Africa
Seoul National University Bundang Hospital
Gyeonggi-do, 13620, South Korea
Seoul National Uni Hospital
Seoul, 110-744, South Korea
Yonsei University Severance Hospital
Seoul, 120-752, South Korea
Kyunghee University Hospital
Seoul, 130-702, South Korea
Samsung Medical Centre
Seoul, 135-170, South Korea
Korea University Anam Hospital
Seoul, 136-705, South Korea
Hospital General Universitario de Elche
Elche, Alicante, 03202, Spain
Hospital Universitario Son Espases
Palma de Mallorca, Balearic Islands, 07014, Spain
Hospital Son Llatzer
Palma de Mallorca, Balearic Islands, 07198, Spain
Corporacio Sanitaria Parc Tauli
Sabadell, Barcelona, Barcelona, 08208, Spain
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008, Spain
Hospital Provincial de Castellon
Castellon, Castellon, 12002, Spain
Hospital Universitario Reina Sofia
CĂ³rdoba, Cordoba, 14004, Spain
IInstituto Oncologico de San Sebastian, Oncologikoa
Donostia / San Sebastian, Guipuzcoa, 20014, Spain
Hospital de Donostia
Donostia / San Sebastian, Guipuzcoa, 20080, Spain
Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), OncologĂa
A Coruña, LA Coruna, 15006, Spain
Complejo Hospitalario Universitario de Santiago (CHUS)
Santiago de Compostela, LA Coruna, 15706, Spain
Hospital Universitari Arnau de Vilanova de Lleida
Lleida, Lerida, 25198, Spain
Hospital Clinico Universitario Virgen de la Victoria
MĂ¡laga, Malaga, 29010, Spain
Hospital Universitario de Canarias
San CristĂ³bal de La Laguna, Tenerife, 38320, Spain
Centro OncolĂ³gico Gallego JosĂ© Antonio Quiroga y Piñeiro, Servicio de Oncologia
A Coruña, 15009, Spain
Hospital del Mar
Barcelona, 08003, Spain
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, 08035, Spain
Hospital ClĂnic i Provincial
Barcelona, 08036, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, 08041, Spain
Hospital Duran i Reynals
Barcelona, 08908, Spain
Hospital Universitari Germans Trias i Pujol
Barcelona, 08916, Spain
Hospital Juan Ramon Jimenez
Huelva, 21005, Spain
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico
Jaén, 23007, Spain
Centro Oncologico MD Anderson Internacional
Madrid, 28033, Spain
Hospital Ramon y Cajal
Madrid, 28034, Spain
Hospital Universitario ClĂnico San Carlos
Madrid, 28040, Spain
Hospital General Universitario Gregorio Marañon
Madrid, 28041, Spain
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
Centro Integral Oncologico Clara Campal (CIOCC)
Madrid, 28050, Spain
Hospital General Universitario J.M Morales Meseguer
Murcia, 30008, Spain
Hospital Clinico Universitario de Salamanca
Salamanca, 37007, Spain
Hospital Universitario Virgen Macarena
Seville, 41009, Spain
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
Hospital Univ. Nuestra Señora de Valme
Seville, 41014, Spain
Complejo Hospitalario de Toledo- H. Virgen de la Salud
Toledo, 45004, Spain
Instituto Valenciano Oncologia
Valencia, 46009, Spain
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia
Valencia, 46015, Spain
Hospital Universitario la Fe
Valencia, 46026, Spain
Hospital Universitario Miguel Servet
Zaragoza, 50009, Spain
Sahlgrenska Universitetssjukhuset
Gothenburg, 40036, Sweden
Uni Hospital Linkoeping
Linköping, 58185, Sweden
Karolinska University Hospital
Stockholm, S-118 83, Sweden
Norrlands Universitetssjukhus, UmeĂ¥, Cancercentrum
UmeĂ¥, 90185, Sweden
Akademiska sjukhuset, Onkologkliniken
Uppsala, 75185, Sweden
Universitaetsspital Basel
Basel, 4031, Switzerland
Hôpitaux Universit. de Genève Gynécologique - Oncologie
Geneva, 1211, Switzerland
Luzerner Kantonsspital
Lucerne, 6004, Switzerland
Kantonsspital St. Gallen
Sankt Gallen, 9007, Switzerland
Brust-Zentrum ZĂ¼rich AG Seefeldstrasse 214 ZĂ¼rich
Zurich, 8008, Switzerland
Changhua Christian Hospital
Changhua, 500, Taiwan
Kaohsiung Medical Uni Chung-Ho Hospital
Kaohsiung City, 807, Taiwan
Taichung Veterans General Hospital
Taichung, 407, Taiwan
National Cheng Kung Uni Hospital
Tainan, 704, Taiwan
Veterans General Hospital
Taipei, 00112, Taiwan
National Taiwan Uni Hospital
Taipei, 100, Taiwan
Tri-Service General Hospital, Division of General Surgery
Taipei, 114, Taiwan
Chiang Rai Prachanukraw Hospital
Chiang Rai, 57000, Thailand
Lopburi Cancer Hospital
Lopburi, 15000, Thailand
Buddhachinaraj Phitsanulok Hospital
Phitsanulok, 65000, Thailand
Songklanagarind Hospital
Songkhla, 90110, Thailand
Surat Thani Hospital
Surat Thani, 84000, Thailand
Cherkassy Regional Oncological Hospital
Cherkassy, 18009, Ukraine
State Medical Academy
Dnipropetrovsk, 43102, Ukraine
Ivano-Frankivsk Regional Oncology Center
Ivano-Frankivsk, 76018, Ukraine
Kyiv City Clinical Oncological Center, Day Hospital Department for Oncological patients
Kiev, 03115, Ukraine
Volyn Regional Oncology Dispensary
Lutsk, 43018, Ukraine
Lvov State Regional Oncology Medical & Diagnostic Center
Lviv, 79031, Ukraine
Ternopil State Medical Academy
Ternopil, 46023, Ukraine
Royal Berkshire Hospital
Berkshire, RG1 5AN, United Kingdom
Velindre Cancer Centre
Cardiff, CF14 2TL, United Kingdom
Cheltenham General Hospital
Cheltenham, GL53 7AN, United Kingdom
Colchester General Hospital
Colchester, Essex, CO4 5JL, United Kingdom
University Hospital coventry
Coventry, CV2 2DX, United Kingdom
Western General Hospital
Edinburgh, EH4 2XU, United Kingdom
Royal Devon & Exeter Hospital
Exeter, EX2 5DW, United Kingdom
Ipswich Hospital
Ipswich, IP4 5PD, United Kingdom
St James Uni Hospital
Leeds, LS9 7TF, United Kingdom
St. Bartholomew'S Hospital
London, EC1A 7BE, United Kingdom
UCL Hospital NHS Trust
London, NW1 2PG, United Kingdom
Royal Marsden Hospital
London, SW3 6JJ, United Kingdom
Christie Hospital
Manchester, M20 4BX, United Kingdom
The Clatterbridge Cancer Ctr For Oncolgy
Metropolitan Borough of Wirral, CH63 4JY, United Kingdom
Mount Vernon Hospital
Northwood, HA6 2RN, United Kingdom
Nottingham City Hospital
Nottingham, NG5 1PB, United Kingdom
Churchill Hospital
Oxford, OX3 7LJ, United Kingdom
Peterborough City Hospital, Edith Cavell Campus
Peterborough, PE3 9GZ, United Kingdom
Queen Alexandra Hospital
Portsmouth, PO6 3LY, United Kingdom
Royal Preston Hosp
Preston, PR2 9HT, United Kingdom
Weston Park Hospital
Sheffield, S10 2SJ, United Kingdom
Uni Hospital of North Staffordshire
Stoke-on-Trent, ST4 6QG, United Kingdom
Royal Marsden Hosp NHS Fnd
Sutton, SM2 5PT, United Kingdom
Royal Cornwall Hospital
Truro, TR1 3LJ, United Kingdom
New Cross Hospital
Wolverhampton, WV10 0QP, United Kingdom
Related Publications (9)
Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, Gelber RD, Restuccia E, Im YH, Huang CS, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Raimbault A, McConnell R, Monturus E, de Azambuja E, Gomez HL, Bliss J, Viale G, Bines J, Piccart M; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update. J Clin Oncol. 2024 Nov;42(31):3643-3651. doi: 10.1200/JCO.23.02505. Epub 2024 Sep 11.
PMID: 39259927DERIVEDde Azambuja E, Agostinetto E, Procter M, Eiger D, Ponde N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T; APHINITY Steering Committee and Investigators. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO Open. 2023 Feb;8(1):100772. doi: 10.1016/j.esmoop.2022.100772. Epub 2023 Jan 19.
PMID: 36681013DERIVEDGelber RD, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M; APHINITY Steering Committee and Investigators. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. Eur J Cancer. 2022 May;166:219-228. doi: 10.1016/j.ejca.2022.01.031. Epub 2022 Mar 18.
PMID: 35313167DERIVEDBines J, Clark E, Barton C, Restuccia E, Procter M, Sonnenblick A, Fumagalli D, Parlier D, Arahmani A, Baselga J, Viale G, Reaby LL, Frank E, Gelber RD, Piccart M, Jackisch C, Petersen JA. Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. Br J Cancer. 2021 Jul;125(1):38-47. doi: 10.1038/s41416-021-01323-y. Epub 2021 Apr 7.
PMID: 33828257DERIVEDPiccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pienkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber RD, Viale G, Thomssen C; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. J Clin Oncol. 2021 May 1;39(13):1448-1457. doi: 10.1200/JCO.20.01204. Epub 2021 Feb 4.
PMID: 33539215DERIVEDBines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, Van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber RD, Piccart M, Mobus V, de Azambuja E; APHINITY Steering Committee and Investigators. Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Clin Breast Cancer. 2020 Apr;20(2):174-181.e3. doi: 10.1016/j.clbc.2019.06.016. Epub 2019 Sep 5.
PMID: 31924513DERIVEDLuo Y, Li W, Jiang Z, Zhang Q, Wang L, Mao Y, Tjan-Heijnen VCG, Im SA, McConnell R, Bejarano S, Fumagalli D, Bines J, Wang B, Garg A, Kirschbrown WP, Xu B. Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. Anticancer Drugs. 2019 Sep;30(8):866-872. doi: 10.1097/CAD.0000000000000808.
PMID: 31305270DERIVEDKirschbrown WP, Kagedal M, Wang B, Lindbom L, Knott A, Mack R, Monemi S, Nijem I, Girish S, Freeman C, Fumagalli D, McConnell R, Jerusalem G, Twelves C, Baselga J, von Minckwitz G, Bines J, Garg A. Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer Chemother Pharmacol. 2019 Jun;83(6):1147-1158. doi: 10.1007/s00280-019-03826-1. Epub 2019 Apr 11.
PMID: 30976844DERIVEDvon Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5.
PMID: 28581356DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Medical Communications
- Organization
- Hoffmann-La Roche
Study Officials
- STUDY DIRECTOR
Clinical Trials
Hoffmann-La Roche
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 20, 2011
First Posted
May 24, 2011
Study Start
November 8, 2011
Primary Completion
December 19, 2016
Study Completion
November 28, 2024
Last Updated
November 28, 2025
Results First Posted
January 5, 2018
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will share
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing